CG Oncology, Inc. Payments to Acquire Short-term Investments
CG Oncology, Inc. (CGON) reported Payments to Acquire Short-term Investments of $529.85 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-08.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2025-08-08
- CG Oncology, Inc. payments to acquire short-term investments for the quarter ending 2025-06-30 was $167.96M, a 18.60% decline year-over-year.
- CG Oncology, Inc. payments to acquire short-term investments for the quarter ending 2025-03-31 was $361.89M, a 20.16% decline year-over-year.
- CG Oncology, Inc. payments to acquire short-term investments for the quarter ending 2024-12-31 was $217.07M, a 1.19% increase year-over-year.
- CG Oncology, Inc. payments to acquire short-term investments for the quarter ending 2024-09-30 was $169.24M, a 11.88% decline year-over-year.
- CG Oncology, Inc. payments to acquire short-term investments for fiscal 2024 was $1.05B, a 102.07% increase from fiscal 2023.
- CG Oncology, Inc. payments to acquire short-term investments for fiscal 2023 was $517.61M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2025-06-30 | $167.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $529.85M 10-Q · filed 2025-08-08 | $746.92M derived: sum of 3 quarters · filed 2025-08-08 | $916.15M derived: sum of 4 quarters · filed 2025-08-08 |
| 2025-03-31 | $361.89M 10-Q · filed 2025-05-13 | $578.96M derived: sum of 2 quarters · filed 2025-05-13 | $748.20M derived: sum of 3 quarters · filed 2025-05-13 | $954.54M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-12-31 | $217.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $386.30M derived: sum of 2 quarters · filed 2025-03-28 | $592.64M derived: sum of 3 quarters · filed 2025-08-08 | $1.05B 10-K · filed 2025-03-28 |
| 2024-09-30 | $169.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $375.58M derived: sum of 2 quarters · filed 2025-08-08 | $828.87M 10-Q · filed 2024-11-12 | $1.04B derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-06-30 | $206.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $659.64M 10-Q · filed 2025-08-08 | $874.15M derived: sum of 3 quarters · filed 2025-08-08 | $1.07B derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $453.30M 10-Q · filed 2025-05-13 | $667.81M derived: sum of 2 quarters · filed 2025-05-13 | $859.86M derived: sum of 3 quarters · filed 2025-05-13 | $892.21M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $214.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $406.56M derived: sum of 2 quarters · filed 2025-03-28 | $438.91M derived: sum of 3 quarters · filed 2025-03-28 | $517.61M 10-K · filed 2025-03-28 |
| 2023-09-30 | $192.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $224.40M derived: sum of 2 quarters · filed 2024-11-12 | $303.10M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $32.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $111.05M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $78.70M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |